Joshua Jacobs, MD
Allergy · Walnut Creek, CANPI 1215920673
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,069,341 of the $1,519,304 with a category attached, or 70.4%. 51 manufacturers reported payments, led by AstraZeneca at 25.1% of the total. Among allergy clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,423 payments — averaging $627.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$382K
- Sanofi$142K
- Teva Pharmaceuticals USA, Inc.$135K
- CSL Behring$135K
- Regeneron Healthcare Solutions, Inc.$134K
- Takeda Pharmaceuticals U.S.A., Inc.$122K
- plus $469K from 45 others
Across 763 payments — averaging $4743.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1.7M
- AstraZeneca$436K
- Novartis$357K
- Takeda Pharmaceuticals U.S.A., Inc.$337K
- Shire North American Group Inc$147K
- Genentech, Inc.$141K
- plus $455K from 11 others
Across 2 payments — averaging $2445.53 each. An ownership or investment interest held by the physician or an immediate family member.
- Consortium Of Independent Immunology Clinics, LLC$5K
What the payments were for
- Consulting fees$240,48416%
- Speaking & faculty fees$1,069,34170%
- Travel & lodging$148,45710%
- Food & beverage$60,6724%
- Education$3490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,519,304 in reported general payments places this provider in the 95th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 42 | $1,925,416 |
| TakhzyroLanadelumab-Flyo | 33 | $1,401,893 |
| IcatibantIcatibant Acetate | 23 | $1,013,486 |
| FirazyrIcatibant Acetate | 11 | $923,782 |
| Dupixent SyringeDupilumab | 67 | $272,979 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $64,758 |
| TezspireTezepelumab-Ekko | 14 | $62,442 |
| Breo ElliptaFluticasone/Vilanterol | 97 | $46,782 |
| XolairOmalizumab | 13 | $33,684 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $25,691 |
| Spiriva RespimatTiotropium Bromide | 18 | $18,884 |
| Qvar RedihalerBeclomethasone Dipropionate | 51 | $17,130 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $12,663 |
| Cromolyn Sodium | 27 | $11,878 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $11,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Firazyr | $122,244 | $2,325,67544 claims |
| CSL BehringHaegarda | $135,001 | $1,925,41642 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $60,340 | $122,157177 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $381,687 | $100,79590 claims |
| Genentech, Inc.Xolair | $6,499 | $33,68413 claims |
| Boehringer IngelheimSpiriva Respimat | $454 | $18,88418 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $135,340 | $17,13051 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $3,027 | $11,87827 claims |
| Hikma Pharmaceuticals USAEpinephrine | $7,400 | $9,08053 claims |
| Covis Pharma GmbHAlvesco | $164 | $4,29016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 allergy providers in California.
Other allergy in Walnut Creek
- Roy OrdenWalnut Creek$16K
- Kelsey IgeWalnut Creek$7K
- Shilpi AnandWalnut Creek$5K
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
- Stephen WongHacienda Heights$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.